Abstract 1400P
Background
Sotorasib has demonstrated robust activity in phase 3 trial in pretreated NSCLC patients (pts) with KRAS G12C mutation. However, its effectiveness and safety in a real-world (RW) setting, particularly when administered after treatment with immune checkpoint inhibitors (ICI), remains to be confirmed.
Methods
Multicenter retrospective study including NSCLC pts who received at least one dose of sotorasib as part of the French expanded access program between February 2021 and April 2022. The primary objective was to evaluate real-world progression-free survival (rwPFS), and the secondary objectives included overall survival (OS) and reporting of sotorasib-related hepatic toxicity.
Results
At time of intermediate database lock a total of 313 pts with data collection completed (out of 446 included) were considered in this analysis. At time of sotorasib initiation: median age 66 years (range [39-85]), males (56%), PS2+ (30%) and smokers (95%). Brain metastases (BM) were present in 116 (37%) pts, with 53% in progression. PD-L1 expression was < 1% in 33%, ≥ 1-49% in 35% and ≥ 50% in 23% of the pts. The median number of lines of treatment before sotorasib was 2.0, and the last treatment before sotorasib included ICI in 164 pts. The median follow-up time was 13.7 months (ms). Median rwPFS was 4.2 ms [95%CI 3.3;4.9], and median OS was 9.3 ms [95%CI 7.9 ;12.3]. Objective response rate (ORR) was 34.3% [95%CI 28.4; 40.1] and disease control rate (DCR) was 64.2%. Median duration of response was 3.9 ms [95%CI 2.9;5.6]. In BM, DCR was 65.9% with 18.7% of ORR. Hepatic grade 3 or 4 treatment-related adverse events (TRAEs) were reported in 7% pts, with ALAT elevation observed in 3.5% and ASAT elevation observed in 2.2% of pts. Among 263 pts who stopped treatment, 42 (16%) discontinued sotorasib due to toxicity, including hepatic toxicity (26 pts), diarrhea (14 pts) and other reasons (8 pts).
Conclusions
Our IFCT-2102 study confirms the effectiveness of sotorasib in pretreated KRAS G12C-NSCLC pts, and its safety profile is manageable with hepatic grade 3 or 4 TRAEs occurring in 7% of pts. Our findings support the use of sotorasib as a treatment option in this population.
Clinical trial identification
NCT05273047.
Editorial acknowledgement
Legal entity responsible for the study
IFCT.
Funding
Amgen.
Disclosure
M. Wislez: Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, Roche, BMS, MSD, AstraZeneca, Sanofi, Novartis, Lilly; Financial Interests, Personal, Speaker’s Bureau: Amgen, MSD, BMS, AstraZeneca, Lilly, Sanofi; Non-Financial Interests, Personal, Non financial benefits, Support for attending meetings and/or travel: Roche, MSD. C. Mascaux: Financial Interests, Personal, Speaker, Consultant, Advisor: GSK, Janssen, Amgen, Kephren, AstraZeneca, MSD, Bristol Myers Squibb, Pfizer, Takeda, Sanofi, Roche, Amgen; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: MSD; Financial Interests, Personal, Other, Uncompensated Relationships: Boehringer Ingelheim. J. Cadranel: Financial Interests, Personal, Advisory Board, Participation to boards: Amgen, Daiichi, Takeda, MSD, Jansen, AZ; Financial Interests, Institutional, Other, prospective: AbbVie; Non-Financial Interests, Principal Investigator, Trials: AZ, AbbVie, Takeda, BI, Daiichi, Pfizer, Novartis, Amgen, Sanofi, Janssen, BMS; Financial Interests, Institutional, Research Grant, Translational research: AbbVie; Financial Interests, Institutional, Research Grant, Preclinical research: Sanofi; Financial Interests, Institutional, Research Grant, Support to academic trial: Pfizer; Financial Interests, Personal, Advisory Board, Participation to Boards: Pfizer; Financial Interests, Institutional, Advisory Board, Participation to boards: Novartis, Sanofi; Financial Interests, Personal, Invited Speaker, Participation to boards: BI. Q. Thomas: Financial Interests, Personal, Speaker, Consultant, Advisor: Amgen, Sanofi, AstraZeneca; Non-Financial Interests, Personal, Non financial benefits, Support for attending meetings and/or travel: Sanofi. A. Swalduz: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Janssen, Roche, Amgen, BMS, Pfizer, Lilly. E. Pichon: Non-Financial Interests, Personal, Non financial benefits, Attending meeting: Takeda; Financial Interests, Personal, Other, Personal payment for educational event: Takeda; Financial Interests, Institutional, Local PI, clinical trials: BeiGene, AstraZeneca, Bristol Myers Squib, Janssen. V. Gounant: Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, Takeda; Non-Financial Interests, Personal, Other, Travel, Accomodations, Expenses: Sanofi, Pfizer. G. Rousseau Bussac: Financial Interests, Institutional, Research Grant: Takeda, AstraZeneca, BMS; Financial Interests, Personal, Speaker’s Bureau: BMS, Takeda; Financial Interests, Personal, Other, Support for attending meetings and/or travel: Sanofi, Boehringer, AstraZeneca. A. Madroszyk Flandin: Financial Interests, Institutional, Research Grant: AstraZeneca, Roche; Financial Interests, Personal, Expert Testimony: AstraZeneca, Roche; Non-Financial Interests, Personal, Non financial benefits, Support for attending meetings and/or travel: AstraZeneca, Pfizer. C. Daniel: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, MSD, Amgen, Sanofi. P. Fournel: Financial Interests, Personal, Advisory Board: BMS, Sanofi, Janssen; Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Amgen; Financial Interests, Personal, Other, Congress invitation: Takeda; Financial Interests, Institutional, Local PI: BMS, Ipsen. F. Guisier: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, BMS, MSD, Roche, Sanofi, Janssen, Pfizer, Takeda; Financial Interests, Institutional, Research Grant: Pfizer, Roche, Takeda. V. Westeel: Financial Interests, Personal, Speaker, Consultant, Advisor, Consulting fees: Amgen; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Bristol Myers Squibb, MSD, Roche, Sanofi; Non-Financial Interests, Personal, Other, Support for attending meetings and/or travel: AstraZeneca, Bristol Myers Squibb, Janssen, MSD, Roche, Sanofi; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Ipsen. All other authors have declared no conflicts of interest.
Resources from the same session
1390P - Real-world characteristics, treatment patterns and outcomes of patients with advanced HER2/ERBB2-mutant non-small cell lung cancer (NSCLC) in France and Germany
Presenter: Petros Christopoulos
Session: Poster session 20
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Presenter: Oscar Jose Juan Vidal
Session: Poster session 20
1392P - Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Karlijn Verkerk
Session: Poster session 20
1393P - Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population
Presenter: Hong Yi Zhang
Session: Poster session 20
1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Presenter: Urska Janzic
Session: Poster session 20
1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Presenter: Didier Debieuvre
Session: Poster session 20
1397P - Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort
Presenter: Jair Bar
Session: Poster session 20
1398P - Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
Presenter: Sophie Ernst
Session: Poster session 20
1399P - Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Presenter: Joshua Reuss
Session: Poster session 20
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20